Drugs / Etifoxine
Etifoxine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT02147548 | Dec 2013 → Oct 2015 | — | Biocodex | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03850301 | Jan 2018 → Jan 2025 overdue | multiple sclerosis | Imperial College London | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Etifoxine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03850301 ↗ |
| Known as | Etifoxina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2106227 ↗ |
| Known as | Etifoxine hydrochloride | “Etifoxine hydrochloride (Stresam®), a treatment indicated for psychosomatic manifestations of anxiety, could be an alternative to benzodiazepines.” PMID 30135030 ↗ Jun 2018 |
| Known as | HOE 36801 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2106227 ↗ |
| Known as | Stresam | “Etifoxine hydrochloride (Stresam®), a treatment indicated for psychosomatic manifestations of anxiety, could be an alternative to benzodiazepines.” PMID 30135030 ↗ Jun 2018 |
| Modality | Small molecule | “Etifoxine is a benzoxaine” NCT03850301 ↗ |
| Route | Oral | “etifoxine, 100 mg, a single oral intake” NCT02147548 ↗ |